The news: The identified gunman in a fatal shooting at the CDC’s Atlanta headquarters had blamed the COVID-19 vaccine for making him ill and suicidal, according to media reports. Our take: Building trust in government health agencies like the CDC is crucial. Physician associations and healthcare and pharma companies can help reinforce the credibility of the medical establishment by partnering with trusted local doctors, pharmacists, and patient advocacy organizations to inform consumers on the benefits of government-endorsed treatments and the risks of being unvaccinated.
The news: The FDA laid out a new FDA PreCheck initiative, aimed at helping pharma companies build US manufacturing plants more quickly. The takeaway: FDA PreCheck may ease manufacturing regulations and trim review time, but navigating real estate, construction, and skilled labor issues still means pharma companies are facing years-long timelines to reshore drug manufacturing. Trump has promised a year or two grace period on his proposed 250% tariffs, but that may not be long enough to get plants up and running. Pharma should look to cut deals—like Apple’s recent tariff exemption granted by Trump after it promised to invest $100 billion in US manufacturing—to guarantee exemptions as long as projects are underway.
The news: Illinois passed a law banning AI therapy, becoming the first state to outlaw the technology for mental health advising. Therapists in the state can still use AI for administrative tasks like transcription and note taking, but not for diagnoses or treatment decisions. Our take: Healthcare providers need to balance the need for AI mental health chatbots with the potential for misuse. Look for digital health companies using tested science and research to develop AI therapy chatbots, transparent practices, and safeguards for flagging problems.
The trend: Healthcare and pharma marketers plan to increase or maintain spending on every digital media channel, according to a May 2025 survey from Mediaocean. The big takeaway: Healthcare and pharma marketers have established their presence and corresponding strategies on still-important media channels such as CTV and search. Digital video and social media are underexplored advertising opportunities for this space.
The situation: The compounded GLP-1 market isn’t dying down as quickly as previously expected. Our take: Online healthcare companies are getting crafty with how they market and sell compounded GLP-1s. Novo and Lilly will keep experimenting with legal tactics to get copycat GLP-1s off the market, but their path to victory in court is unclear. Short of the FDA stepping in—and it doesn’t seem like it will—the battle of pharma vs. compounded weight loss drug sellers will get even messier.
The news: Eli Lilly’s stock plunged about 14% on Thursday as clinical results of its experimental obesity pill orforglipron fell short of Wall Street expectations. Our take: We think Lilly has the edge over Novo, despite Thursday’s market reversal due to Lilly’s obesity pill falling short in its trial. That’s likely just a near-term blip—12% weight loss in a little over a year validates that the medication is quite effective, especially when considering that most people would prefer a pill to injecting themselves. Lilly also has in its favor that Zepbound drives better weight loss results than Wegovy, while it faces less competition from the copycat GLP-1 market since semaglutide is more commonly compounded than tirzepatide.
The news: The maker of the Cologuard at-home colon cancer screening test, Exact Sciences, is buying the rights to a promising blood test for colon cancer. The takeaway: As early colon cancer rates increase, more young people are becoming interested in screening. Blood tests adds another option, and for Exact’s Cologuard, known for irreverent ad campaigns for the at-home stool sample kits, another way to advocate for more screening.
The news: HHS Secretary Robert F. Kennedy Jr. canceled $500 million in federal mRNA grants, eliminating flu, COVID-19, and infectious disease research that used the technology. The Biomedical Advanced Research and Development Authority (BARDA) agency nixed 22 contracts, including ones with Moderna, Pfizer, and AstraZeneca.
The trend: Over half of US adults with health insurance (51%) said they needed a prior authorization for a medical service or treatment in the past two years, according to a July 2025 KFF study. The final word: Prior authorizations can lead to delayed—or even denied—care. To date, health plans have not been held accountable for their increased frequency of coverage denials. That could soon change due to a flurry of bills on prior authorization reform at the state level—but for the time being, insurers’ promises and pledges are more PR spin than actionable improvement.
The news: President Trump said to CNBC on Tuesday that forthcoming tariffs on pharma products imported to the US could reach 250%. It’s the highest rate on pharma tariffs that Trump has mentioned to date. Our take: 250% is an enormous number, but it’s more of a threat than an end result that will impair the sector. Such a high levy rate will likely spur further manufacturing commitments, which is something Big Pharma is prepared for—especially if they’re given 18 months to move more production to the US.
The news: A California court ruled Meta’s collection of menstrual health data violated state privacy laws, per TechCrunch. The takeaway: The Meta case puts tech companies that use health data for ad targeting and marketing on notice. Explicit consent and absolute transparency is not only legally critical around healthcare data, but also key to building trust with consumers.
The trend: Consumers are less satisfied with chain drugstores than with mail-order pharmacies, mass market merchandisers, and supermarket pharmacies, according to JD Power’s US Pharmacy Study. Our take: We expect consumers to increasingly explore different channels for getting their prescriptions, both in-person and online—especially folks in areas affected by drugstore closures. CVS and Walgreens have a built-in advantage of established pharmacy customers, but will lose more of them if they don’t address long lines at the counter and improve their online and in-app capabilities.
The news: Noom is now selling microdoses of compounded GLP-1 semaglutide for weight loss with a lower price tag and fewer side effects. Our take: GLP-1 microdosing is booming on social media trend and although weight loss drugmakers Novo and Lilly have neither studied nor endorsed mini doses, it’s another tactic for telehealth providers like Noom to stay in the weight loss game. We expect GLP-1 microdosing to gain marketing steam among telehealths this year.
The news: President Trump sent letters to 17 pharma companies, demanding they take action to lower drug prices in the US within 60 days. Our take: We think it’s unrealistic to expect pharma companies to willingly cut their profits despite Trump’s escalated demands. Drugmakers called out in the letter will likely wait out Trump’s deadline and see what he threatens next, knowing they could always legally challenge the most-favored nation order. We also expect more pharma companies to make some of their medicines available through the D2C channel, perhaps seeing it as a reasonable good-faith concession that they hope will get Trump to back off the most-favored nation pricing.
The news: Merck is teaming with McKinsey for a generative AI (genAI) program that streamlines clinical study reports (CSRs). The takeaway: GenAI is ideal for time-intensive precise medical writing and frees content creators for oversight and strategic tasks. While Merck and some others are already using it for regulatory filings, those who stall or keep their pilots in the experimentation phase risk losing valuable time-to-market advantages.
The news: Medicare and Medicaid could cover GLP-1s for weight loss as part of a proposed five-year government experiment, according to a report in The Washington Post. Our take: The pilot, albeit not finalized, is a significant about-face from the Trump administration—particularly its top health official, Kennedy. It could be a signal that CMS Administrator Dr. Mehmet Oz is behind the plan, since he’s a bigger proponent of the meds. Still, we’re dubious about how many health plans will commit considering GLP-1s' high costs are a top concern for most insurers.
The news: CVS’s Q2 earnings topped estimates, buoyed by solid performance in its retail pharmacy segment and signs that its health insurance division is finally turning things around. Our take: CVS may not be thriving compared with earlier in the decade, but it’s in a good position relative to most of its rivals. That’s largely because of its diversified footprint across healthcare (pharmacy, insurance, PBM) that prevents the company from being overexposed in one struggling sector. CVS’ ongoing company turnaround could be a good sign for the similarly structured UnitedHealth, DOJ investigations notwithstanding.
The news: More than 60 healthcare and technology players, including Amazon, Apple, Google, UnitedHealth Group, and OpenAI, signed a voluntary pledge put forth by the Trump administration to make it easier for consumers to access their medical data. Our take: It’s not the first time that industry players have pledged to improve health data sharing—but we haven’t seen enough progress due to a lack of accountability or enforcement. Many consumers also likely have concerns about how tech companies will use and protect their personal information.
The trend: Older consumers pick up their prescription medicines in person more often, while Gen Z looks to buy Rx drugs online, per M3 MI’s Consumer Health Study of over 20,000 US adults. The takeaway: Drugmakers can lean into tailored marketing efforts that match age demographics and retail preferences. Amazon Pharmacy doesn’t take ads, but pharma companies can show young people getting Amazon Rx deliveries. On the flip side, feature older actors or promote vaccine messages via retail media in grocery stores.
The news: The trade deal between the US and EU will include a 15% tariff on pharmaceuticals imported from Europe, the White House said. The final word: Pharma companies and industry trade groups had been holding out hope that their medicines imported to the US would be exempt from tariffs. Not getting that reprieve is a setback—but the 15% rate on its own could be seen as a decent outcome, particularly considering that 200% tariffs were threatened and the Section 232 investigation could lead to a higher levy in other countries.